About Sirio Pharma Co.Ltd(300791)
Assurance report on the deposit and use of raised funds in 2021 Huaxing zhuanzi [2022] No. 22 Zhang Jia Jie Tourism Group Co.Ltd(000430) 028 Sirio Pharma Co.Ltd(300791) all shareholders:
We have been entrusted to carry out the verification of the attached special report on the deposit and use of raised funds in 2021 prepared by the board of directors of Sirio Pharma Co.Ltd(300791) (hereinafter referred to as ” Sirio Pharma Co.Ltd(300791) “).
Sirio Pharma Co.Ltd(300791) the responsibility of the board of directors is to provide true, legal and complete relevant materials in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) Prepared in accordance with the provisions of Shenzhen Stock Exchange GEM listed companies No. 21 – special report form on the annual deposit and use of raised funds of Listed Companies in Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies and Shenzhen Stock Exchange GEM listed companies No. 2 – announcement form The special report on the deposit and use of raised funds in 2021 shall be true, accurate and complete without false records, misleading statements or major omissions. Our responsibility is to express assurance opinions on the special report on the deposit and use of raised funds in 2021 prepared by Sirio Pharma Co.Ltd(300791) board of directors based on the implementation of assurance work.
We have carried out the assurance work in accordance with the provisions of other assurance business standards for Chinese certified public accountants No. 3101 – assurance business other than audit or review of historical financial information, so as to obtain reasonable assurance about whether there is no material misstatement in the special report on the deposit and use of raised funds in 2021. In the process of performing assurance work, we implement understanding, inquiry, inspection, recalculation and other procedures that we deem necessary. We believe that our assurance work provides a reasonable basis for expressing opinions.
We believe that the special report on the deposit and use of raised funds in 2021 prepared by Sirio Pharma Co.Ltd(300791) board of directors has been in accordance with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) Prepared in accordance with the provisions of Shenzhen Stock Exchange GEM listed companies No. 21 – special report form on the annual deposit and use of raised funds of Listed Companies in Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies of Shenzhen Stock Exchange and Shenzhen Stock Exchange GEM listed companies No. 2 – announcement form of Shenzhen Stock Exchange GEM listed companies of Shenzhen Stock Exchange, It truthfully reflects the deposit and use of the raised funds in Sirio Pharma Co.Ltd(300791) 2021 in all major aspects.
This assurance report is only used for the purpose of disclosure of Sirio Pharma Co.Ltd(300791) 2021 annual report and shall not be used for any other purpose.
Huaxing certified public accountants, Chinese Certified Public Accountants:
(special general partnership)
Chinese certified public accountant:
Fuzhou, China April 8, 2002
Sirio Pharma Co.Ltd(300791)
Special report on the deposit and use of raised funds in 2021
According to the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies (revised in 2022) issued by the China Securities Regulatory Commission Shenzhen Stock Exchange GEM listed companies No. 21 – special report form on the annual deposit and use of raised funds of listed companies and other relevant provisions of Shenzhen Stock Exchange GEM listed companies No. 2 – standardized operation of GEM listed companies and Shenzhen Stock Exchange GEM listed companies No. 2 – announcement form, The board of directors of Sirio Pharma Co.Ltd(300791) (hereinafter referred to as “the company”) prepared a special report on the annual deposit and actual use of raised funds as of December 31, 2021.
1、 Funds raised by public issuance of convertible corporate bonds
With the approval of the reply on Approving the registration of Sirio Pharma Co.Ltd(300791) issuing convertible corporate bonds to unspecified objects (zjxk [2021] No. 927) issued by China Securities Regulatory Commission (hereinafter referred to as “CSRC”), the company issued 10248929 convertible corporate bonds to unspecified objects, with a face value of 100 yuan each and a total raised capital of 102489200 yuan, After deducting the recommendation fee and underwriting fee of 8.7254 million yuan, the balance of the raised funds of 1016167500 yuan has been transferred to the designated account of the company, including 2.7589 million yuan (excluding tax) of the issuance expenses such as recommendation fee, audit and fee verification fee and lawyer fee, and the net amount of the actually raised funds is 1013408600 yuan. Huaxing Certified Public Accountants (special general partnership) has issued Sirio Pharma Co.Ltd(300791) capital verification report (Huaxing Yan Zi [2021] No. 21 Shenzhen Zhongheng Huafa Co.Ltd(000020) 045) and verified and confirmed the receipt of the above raised funds. As of December 31, 2021, the use and balance of the funds raised by the company’s public issuance of convertible corporate bonds are as follows:
Unit: RMB
Project amount
Received amount of raised funds (underwriting fee and recommendation fee deducted) 101616749529
Less: attorney fees, audit fees, sponsor fees paid but not deducted in the early stage, 275891967 legal information disclosure and other issuance expenses
Net amount of actually raised funds 101340857562
Less: accumulated used raised funds 49011401514
Less: supplementary working capital for account cancellation 298993846
Plus: net amount of interest income of raised funds minus handling charges 147558619
The balance of unused raised funds is 53505970821
2、 Management of raised funds
In order to regulate the management and use of the raised funds and protect the interests of investors, the company, in accordance with the company law Securities law, Shenzhen Stock Exchange’s self regulatory guidelines for listed companies No. 2 – standardized operation of companies listed on the gem, Shenzhen Stock Exchange’s self regulatory guidelines for companies listed on the gem No. 2 – announcement format, Shenzhen Stock Exchange’s GEM listed companies No. 21 – special report form on the annual deposit and use of raised funds of listed companies, and other relevant laws In accordance with the provisions and requirements of laws and regulations and in combination with the actual situation of the company, the Sirio Pharma Co.Ltd(300791) raised funds management system is formulated, and the raised funds are stored in a special account.
(I) funds raised by public issuance of convertible corporate bonds
The company opened a special account for raising funds for public issuance of convertible corporate bonds, and signed the tripartite supervision agreement on raising funds with China Minsheng Banking Corp.Ltd(600016) Shantou branch, Bank Of China Limited(601988) Shantou branch, China Citic Bank Corporation Limited(601998) Shantou branch, Guangdong Huaxing Bank Co., Ltd. Shantou branch and the sponsor China Merchants Securities Co.Ltd(600999) Shantou branch; Sirio Pharma Co.Ltd(300791) Technology (Anhui) Co., Ltd., the implementation subject of the company’s raised investment project, signed the tripartite supervision agreement on raised funds with Bank Of China Limited(601988) MAANSHAN branch, China Minsheng Banking Corp.Ltd(600016) Shantou branch, China Citic Bank Corporation Limited(601998) Shantou branch and the sponsor China Merchants Securities Co.Ltd(600999) Shantou branch. There is no significant difference between the tripartite supervision agreement and the model tripartite supervision agreement of Shenzhen Stock Exchange, which complies with the guidelines for self discipline supervision of listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM and other relevant provisions, and there is no problem in the performance of the tripartite supervision agreement.
As of December 31, 2021, the balance of funds raised from the public issuance of convertible corporate bonds that the company has not used is 53505970821 yuan, and there is no pledge guarantee. The details are as follows:
Unit: RMB
Deposit bank account nature bank account number amount
China Citic Bank Corporation Limited(601998) shantou branch special user of raised funds 811090101280128935717366706044
China Minsheng Banking Corp.Ltd(600016) Shantou branch fund raising special user 632869267 – Business Department
Bank Of China Limited(601988) Shantou branch fund raising special user 726374407038-
Guangdong Huaxing Bank Co., Ltd. Shantou branch fund raising special user 8028801 Yang Guang Co.Ltd(000608) 53-
China Minsheng Banking Corp.Ltd(600016) Shantou branch fund raising special user 6329224639223653946
Bank Of China Limited(601988) MAANSHAN Development Zone special user of raised funds 1887617275052915610831 sub branch
China Citic Bank Corporation Limited(601998) Shantou branch fund raising special user 811090101 Shanghai Taisheng Wind Power Equipment Co.Ltd(300129) 2107-
Bank Of China Limited(601988) MAANSHAN Development Zone financial products 24000000000 sub branch
Total 53505970821
As of December 31, 2021, the 632869267 account of the company’s China Minsheng Banking Corp.Ltd(600016) Shantou branch business department, Bank Of China Limited(601988) Shantou branch 726374407038 account and the 8028801 Yang Guang Co.Ltd(000608) 53 account of Shantou branch of Guangdong Huaxing Bank Co., Ltd. have been closed.
3、 Actual use of raised funds during the reporting period
As of December 31, 2021, the actual use of funds raised by public issuance of convertible corporate bonds is shown in the attached table comparison table of fund use of projects raised by public issuance of convertible corporate bonds.
4、 Change the use of funds of raised investment projects
There is no change in the investment projects of raised funds during the reporting period.
5、 Problems in the use and disclosure of raised funds
The company has timely, truly, accurately and completely disclosed the use of the company’s raised funds and relevant information, and there is no violation of the management of raised funds.
Attached table: comparison table of fund use of projects raised by public issuance of convertible corporate bonds
Sirio Pharma Co.Ltd(300791) board of directors April 8, 2002 schedule:
Comparison table of fund use of projects raised by public issuance of convertible corporate bonds
As of December 31, 2021
Unit: RMB 10000
The total amount of raised funds is 10134086, and the total amount of raised funds invested in the reporting period is 4901140
Total amount of raised funds with changed purposes during the reporting period-
Accumulated total raised funds with changed purposes – accumulated total raised funds invested 4901140
Proportion of total raised funds with accumulative change of purpose
